安罗替尼三线及三线后治疗非小细胞肺癌疗效及生存质量的meta分析

Meta analysis of the effect and safety of anlotinib to non-small cell lung cancer for third-line and further therapy

目的:评估安罗替尼对非小细胞肺癌(NSCLC)三线及三线以后治疗的有效性及安全性。方法:采用meta分析对随机对照试验进行系统评价。结果:疾病控制率(OR=0.14,95%CI 0.11~0.17,P<0.00001),客观缓解率(OR=0.08,95%CI 0.03~0.21,P<0.00001),总生存期(OR=0.71,95%Cl 0.55~0.89,P<0.00001),无进展生存期(OR=0.26,95%Cl 0.22~0.30,P<0.00001)。不良反应,如高血压(OR=11.95,95%CI 8.44~16.92,P<0.00001),高血压超过3级(OR=21.92,95%CI 6.09~78.97,P<0.00001),疲劳(OR=2.32,95%CI 1.5~3.58,P=0.0001),呕吐(OR=1.64,95%CI 1.09~2.45,P=0.02),腹泻(OR=3.12,95%CI 2.16~4.51,P<0.00001)。结论:在非小细胞肺癌第三和第三阶段后用安罗替尼治疗可显著提高疗效,但也明显提高高血压等不良反应的发生。

Objective:To assess the safety and efficacy of anlotinib for the third-line and subsequent treatment of patients with non-small cell lung cancer(NSCLC).Methods:The randomized controlled experiments were systematically evaluated by meta-analysis.Result:Disease control rate(OR=0.14,95%CI 0.11-0.17),objective response rate(OR=0.08,95%CI 0.03-0.21),overall survival(OR=0.71,95%Cl 0.55-0.89)and progression-free survival(OR=0.26,95%Cl 0.22-0.30)showed highly statistical significance(P<0.00001).Occurrence of adverse reactions such as hypertension(OR=11.95,95%CI 8.44-16.92,P<0.00001),hypertension beyond level 3(OR=21.92,95%CI 6.09-78.97,P<0.00001),fatigue(OR=2.32,95%CI 1.5-3.58,P=0.0001),vomiting(OR=1.64,95%CI 1.09-2.45,P=0.02)and diarrhea(OR=3.12,95%CI 2.16-4.51,P<0.00001)also showed highly statistical significance.Conclusion:The treatment of NSCLC with anlotinib as the third and post third stages therapy can significantly improve the efficacy,however,the incidence of adverse reactions such as hypertension and so on will be greatly increased.